Celladon Corporation Announces Appointments of Dr. Peter Honig and Dr. Patrick Yang to Its Board of Directors

Celladon Corporation Announces Appointments of Dr. Peter Honig and Dr. Patrick
Yang to Its Board of Directors

SAN DIEGO, March 3, 2014 (GLOBE NEWSWIRE) -- Celladon Corporation
(Nasdaq:CLDN), a clinical-stage biotechnology company focused on developing
novel therapies by applying its leadership position in the field of SERCA
enzymes, today announced it has appointed Dr. Peter K. Honig and Dr. Patrick
Y. Yang to its Board of Directors. The company also announced that concurrent
with these appointments, Dr. Johan Kördel will step down from his current role
as director.

"We believe the knowledge, insight and years of industry experience that Dr.
Honig and Dr. Yang will bring to our board will be invaluable in successfully
guiding the company over the next several years," said Krisztina Zsebo Ph.D.,
President and CEO of Celladon Corporation.

"Both Peter and Pat bring decades of extensive industry experience at leading
biotechnology and pharmaceutical organizations and we expect they will provide
valuable contributions to the Board going forward. We also thank Johan for his
contributions to Celladon over the past years," added Michael Narachi,
Chairman of the Board of Celladon Corporation.

Dr. Peter K. Honig currently serves as the Head of Global Regulatory Affairs
at AstraZeneca, Inc., a global innovation-driven biopharmaceutical company
specializing in the discovery, development, manufacturing and marketing of
prescription medicines. Prior to this position, Dr. Honig served as Senior
Vice President, Worldwide Regulatory Affairs and Product Safety at Merck &
Company. Dr. Honig was Merck's Vice President, Worldwide Product Safety and
Quality Assurance. Prior to Merck, Dr. Honig held various positions at the FDA
including Director of the Office of Drug Safety in the FDA's Center for Drug
Evaluation and Research. Dr. Honig received his B.A. in History from Columbia
College of Columbia University, his M.D. from the Columbia College of
Physicians & Surgeons and his M.P.H from Columbia University School of Public
Health. Dr. Honig also serves as a director of Orexigen Therapeutics, Inc.
(Nasdaq:OREX), a biopharmaceutical company focused on the treatment of

Dr. Patrick Yang recently retired from F. Hoffman-La Roche AG, a leading
global pharmaceutical and diagnostics company, where he served as Global Head
of Pharmaceutical Technical Operations based in Switzerland. In this role, Dr.
Yang was responsible for Roche's pharmaceutical and biotech manufacturing
operations, process development, quality, regulatory, supply management,
distribution, and procurement functions. Previously, Dr. Yang worked for
Genentech, a leading biotechnology company, where his most recent position was
Executive Vice President of Product Operations, responsible for Genentech's
manufacturing, engineering, process development, regulatory, quality,
compliance, and supply chain management functions. Prior to Genentech, Dr.
Yang held several leadership roles at Merck, including Vice President of
Asia/Pacific Operations and Vice President of Supply Chain Management. He also
previously worked at General Electric Co. and Life Systems, Inc. in research,
development, and manufacturing operations.

Dr. Yang currently serves on the board of directors of Tesoro Corporation
(NYSE:TSO), an independent refiner and marketer of petroleum products, and on
the board of directors of Codexis, Inc. (Nasdaq:CDXS), a company in the
development and production of custom industrial enzymes for use in the
pharmaceutical, chemical and biofuel production.

About Celladon

We are a clinical-stage biotechnology company applying our leadership position
in the field of calcium dysregulation by targeting SERCA enzymes to develop
novel therapies for diseases with tremendous unmet medical needs.
Sarco/endoplasmic reticulum Ca2+-ATPase, or SERCA, enzymes are a family of
enzymes that play an integral part in the regulation of intra-cellular calcium
in all human cells. Calcium dysregulation is implicated in a number of
important and complex medical conditions and diseases, such as heart failure,
which is a clinical syndrome characterized by poor heart function, resulting
in inadequate blood flow to meet the body's metabolic needs, as well as
diabetes and neurodegenerative diseases. Our therapeutic portfolio for
diseases characterized by SERCA enzyme deficiency includes both gene therapies
and small molecule compounds. MYDICAR, our most advanced product candidate,
uses gene therapy to target SERCA2a, which is an enzyme that becomes deficient
in patients with heart failure. In addition, we have identified a number of
potential first-in-class compounds addressing novel targets in diabetes and
neurodegenerative diseases with our small molecule platform of SERCA2b

Forward-Looking Statements

Statements contained in this press release regarding matters that are not
historical facts are "forward-looking statements" within the meaning of the
Private Securities Litigation Reform Act of 1995. Such statements include, but
are not limited to, statements regarding Celladon's plans to research, develop
and commercialize product candidates. Because such statements are subject to
risks and uncertainties, actual results may differ materially from those
expressed or implied by such forward-looking statements. These forward-looking
statements are based upon Celladon's current expectations and involve
assumptions that may never materialize or may prove to be incorrect. Actual
results and the timing of events could differ materially from those
anticipated in such forward-looking statements as a result of various risks
and uncertainties, which include, without limitation, risks associated with
the process of conducting product development activities and clinical trials
and obtaining regulatory approval to commercialize product candidates, as well
as our reliance on third parties and the need to raise additional funding when
needed in order to conduct our business. These and other risks and
uncertainties are described more fully in Celladon's filings with the
Securities and Exchange Commission, including without limitation its
Registration Statement on Form S-1 that was originally filed with the
Securities and Exchange Commission on October 10, 2013, and the amendments
thereto. All forward-looking statements contained in this press release speak
only as of the date on which they were made. Celladon undertakes no obligation
to update such statements to reflect events that occur or circumstances that
exist after the date on which they were made.

CONTACT: Fredrik Wiklund
         Vice President, Corporate Development
         and Investor Relations
         +1- 858-432-7215

Celladon Corporation Logo
Press spacebar to pause and continue. Press esc to stop.